MARKET

LGND

LGND

Ligand Pharma
NASDAQ
286.94
-11.77
-3.94%
After Hours: 286.94 0 0.00% 16:15 11/19 EST
OPEN
300.09
PREV CLOSE
298.71
HIGH
301.72
LOW
286.00
VOLUME
168.81K
TURNOVER
--
52 WEEK HIGH
326.63
52 WEEK LOW
175.89
MARKET CAP
5.74B
P/E (TTM)
125.29
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LGND last week (1109-1113)?
Weekly Report · 3d ago
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Dow Jones · 11/11 15:35
Ligand Pharmaceuticals Price Target Raised to $350.00/Share From $345.00 by Barclays
Dow Jones · 11/11 15:35
Barclays Maintains Overweight on Ligand Pharmaceuticals, Raises Price Target to $350
Benzinga · 11/11 15:25
Ligand price target raised to $350 from $345 at Barclays
TipRanks · 11/11 10:20
Barclays Sticks to Their Buy Rating for Ligand Pharma (LGND)
TipRanks · 11/11 09:15
Weekly Report: what happened at LGND last week (1102-1106)?
Weekly Report · 11/09 09:45
Ligand Pharmaceuticals Is Maintained at Buy by Citigroup
Dow Jones · 11/05 22:33
More
About LGND
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.

Webull offers Ligand Pharmaceuticals Inc stock information, including NASDAQ: LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.